Literature DB >> 11585736

Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(-/-) mice.

O J Sansom1, L A Stark, M G Dunlop, A R Clarke.   

Abstract

Numerous studies have indicated that exposure to nonsteroidal anti-inflammatory drugs is associated with a lowered risk of colorectal cancer. However, analyses of the effect of aspirin upon tumorigenesis in Apc(Min/+) mice have yielded contrasting results. We show that adult dietary exposure to aspirin does not suppress intestinal tumorigenesis in Apc(Min/+) mice, but that continual exposure from the point of conception does. To test whether this regime could suppress the phenotype of murine models of hereditary nonpolyposis colorectal cancer, Msh2-deficient mice were exposed to aspirin. This did not modify the mutator phenotype of Msh2(-/-) mice, but weakly extended survival. Finally, we analyzed (Apc(Min/+), Msh2(-/-)) mice and found that lifetime aspirin exposure significantly delayed the onset of both intestinal and mammary neoplasia. Thus embryonic and perinatal exposure to aspirin suppresses neoplasia specifically associated with the loss of Apc function, opening a potential window of opportunity for nonsteroidal anti-inflammatory drug intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585736

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model.

Authors:  Michael A McIlhatton; Jessica Tyler; Laura A Kerepesi; Tina Bocker-Edmonston; Melanie H Kucherlapati; Winfried Edelmann; Raju Kucherlapati; Levy Kopelovich; Richard Fishel
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-24

Review 2.  Chemoprevention of hereditary colon cancers: time for new strategies.

Authors:  Luigi Ricciardiello; Dennis J Ahnen; Patrick M Lynch
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 3.  Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system.

Authors:  Denis E Corpet; Fabrice Pierre
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

4.  Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention.

Authors:  Delphine Lissa; Laura Senovilla; Santiago Rello-Varona; Ilio Vitale; Mickaël Michaud; Federico Pietrocola; Alice Boilève; Florine Obrist; Chloé Bordenave; Pauline Garcia; Judith Michels; Mohamed Jemaà; Oliver Kepp; Maria Castedo; Guido Kroemer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

5.  Cancer and inflammation: an aspirin a day keeps the cancer at bay.

Authors:  Marina Mione; Leonard I Zon
Journal:  Curr Biol       Date:  2012-07-10       Impact factor: 10.834

6.  Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMin+ mouse.

Authors:  S Sale; R G Tunstall; K C Ruparelia; P C Butler; G A Potter; W P Steward; A J Gescher
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

Review 7.  Aspirin in the Prevention of Colorectal Neoplasia.

Authors:  David A Drew; Andrew T Chan
Journal:  Annu Rev Med       Date:  2020-10-09       Impact factor: 13.739

8.  Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂.

Authors:  Yi Feng; Stephen Renshaw; Paul Martin
Journal:  Curr Biol       Date:  2012-05-31       Impact factor: 10.834

9.  Age-related difference in susceptibility of Apc(Min/+) mice towards the chemopreventive efficacy of dietary aspirin and curcumin.

Authors:  S Perkins; A R Clarke; W Steward; A Gescher
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis.

Authors:  Brian K Reuter; Xiao-Jing Zhang; Mark J S Miller
Journal:  BMC Cancer       Date:  2002-08-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.